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Abstract Studies have suggested a possible role for
Blastocystis hominis and Dientamoeba fragilis in the
etiology of irritable bowel syndrome (IBS). We studied
the prevalence of B. hominis and D. fragilis in patients with
IBS-diarrhea (IBS-D). Three hundred and thirty patients
were enrolled, 171 (52%) with IBS-D and 159 (48%) were
controls, respectively. Stool microscopy, culture, and
polymerase chain reaction (PCR) for B. hominis and D.
fragilis were done. B. hominis was positive by stool
microscopy in 49% (83/171) of IBS compared to 24%
(27/159) in control (p<0.001). B. hominis culture was
positive in 53% (90/171) in IBS compared to 16% (25/159)
in control (p<0.001). B. hominis PCR was positive in 44%
(75/171) in IBS compared to 21% (33/159) in control (p<
0.001). D. fragilis microscopy was positive in 3.5% (6/171)
in IBS-D compared to 0.6% (1/159) in control (p=0.123).
D. fragilis culture was positive in 4% (7/171) in IBS
compared to 1.3% (2/159) in control (p=0.176). D. fragilis
PCR was positive in 4% (6/171) in IBS-D compared to 0%
(0/159) in control (p=0.030). B. hominis is common, while
D. fragilis was less prevalent in our patients with IBS-D. B.
hominis and D. fragilis culture had a better yield compared
to stool microscopy and PCR.
Introduction
Parasitic infections afflict a wide range of populations in
both urban and rural areas throughout the world. The direct
impact of protozoan parasites on human is considerable in
the third world countries with poor sanitation and quality of
drinking water (Zonta et al. 2010). Parasitic infections such
as Blastocystis hominis and Dientamoeba fragilis are
associated with abdominal pain, bloating, and alteration of
bowel habits resembling irritable bowel syndrome (IBS;
Yakoob et al. 2004; Johnson et al. 2004). However, a
diagnosis of IBS is based on ROME III criteria indepen-
dently of specific stool collection and testing methods
recommended for detection of parasites (Drossman 2006).
Also, the methods commonly used to diagnose parasitic
infections have a poor yield, and hence, these infections are
never diagnosed. The prevalence of these parasites is
highest in areas of poor sanitation and drinking water
treatment as they are transmitted by fecal-oral route.
A significantly increased level of IgG2 levels against B.
hominis was found in IBS patients compared with asymp-
tomatic controls, indicating that the predominant response
in these patients may be directed to carbohydrate antigens
(Hussain et al. 1997). A number of studies have incrimi-
nated D. fragilis as a cause of IBS, allergic colitis, and
diarrhea in human immunodeficiency virus patients (Johnson
et al. 2004). In a recent study, a high prevalence of D. fragilis
was reported in fecal samples collected from patients
attending complementary medicine practitioners in the
British Isles (Windsor et al. 2002). Approximately 25% of
these stated intestinal symptoms, ranging from acute
gastroenteritis to chronic intestinal symptoms, while similar
in proportion did not report having intestinal symptoms. It is
also noteworthy that over half of the D. fragilis positive
samples were found in combination with B. hominis as
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previously observed (Stensvold et al. 2007; Schuster and
Jackson 2009; Stark et al. 2005; Norberg et al. 2003). B.
hominis is a common human intestinal parasite that is
commonly found in stool on examination. It can be easily
demonstrated by light microscopy, culture, and polymerase
chain reaction (PCR) examination of stool samples
(Norberg et al. 2003; Zaman and Khan 1994). The
pathogenic role of B. hominis is still controversial as it is
frequently found not only in individuals with enteric
symptoms but also in apparently healthy and asymptomatic
subjects (Silberman et al. 1996). It is thought that genotypic
difference exists between the asymptomatic and symptomatic
B. hominis isolates (Stensvold et al. 2006; Yoshikawa et al.
2000). The aim of this study was to determine the prevalence
of B. hominis and D. fragilis in patients with symptoms of




A total of 330 stool samples were examined that were
obtained from patients fulfilling Rome III criteria of IBS-D
in 171 (52%) and 159 (48%) controls who attended the
gastroenterology outpatient clinic at the Aga Khan Univer-
sity, Karachi between January 2008 and December 2009,
respectively (Drossman 2006). The mean age of patients
with IBS-D was 40±15, age range 16–83 years, and male:
female ratio of 117:54. In control group, 159 (48%) were
healthy volunteers with mean age 42±14. These patients
underwent thorough history, physical examination, com-
plete blood count, serum creatinine, electrolytes, and stool
microscopy, culture, and PCR for B. hominis and D.
fragilis. These patients had intact immunity. The study
was approved by institutional ethics review committee.
All the stool specimens were processed by stool
microscopy for B. hominis and D. fragilis. Stool culture
was done for B. hominis and D. fragilis. DNA was
extracted from the unfixed stool specimen, and it was used
for PCR for B. hominis and D. fragilis. A note was made of
the presence of other parasites such as Giardia lamblia,
Entamoeba species, and Cryptosporidium, and these
patients, ten in number, were excluded while no patient
demonstrated Enterobius vermicularis. In previous study,
D. fragilis mono-nucleated or bi-nucleated forms have been
documented in the lumen of E. vermicularis (Johnson et al.
2004). A microbiological investigation was also performed
to detect Salmonella spp., Campylobacter jejuni, Clostrid-
ium difficile, and Vibrio cholerae. However, a viral screen
was not carried out on stool specimens in view of
restriction of cost.
Microscopy of fecal smear
Fecal sample microscopy for demonstrating B. hominis
was done as described before (Zaman and Khan 1994);
approximately 2 mg of feces was emulsified on a glass
slide in one drop of physiologic saline and covered with a
cover slip. A similar preparation was made on another
slide using Lugol's iodine. These preparations were
examined under both the low power (×10) and high dry
(×40) objectives. Specimen smear was fixed in sodium
acetate/acetic acid/formalin (SAF) and then stained with
modified trichrome stain to look for D. fragilis (Johnson et
al. 2004).
Culture
Jones medium without starch was used for culturing B.
hominis as described before (Zaman and Khan 1994). The
cultures were incubated at 37°C and examined after 48 h.
If no B. hominis were seen up to further 2 days, they were
regarded as negative. The sediment was examined under
both the low power (×10) and high dry (×40) objectives.
D. fragilis culture was done in Robinson's medium as
previously described (Windsor et al. 2003).
Extraction of genomic DNA
Stool DNA was extracted by using Stool DNA Extraction
kit (Qiagen) according to the manufacturer's protocol.
Extracted DNA was stored at −20°C until PCR was carried
out for B. hominis and D. fragilis
PCR
The primers used were previously described (Table 1). The
primer pair SR1F and SR1R was used to amplify a
conserved region of the B. hominis small subunit (SSU)
rRNA, while primer TRD3 and TRD5 design was based on
the sequence of the of SSU rRNA gene of D. fragilis
(Silberman et al. 1996; Yoshikawa et al. 2000; Table 1).
The PCR reaction volume was 25 μl that comprised of
2.5 μl of 10× PCR buffer (Promega), 2.0 μl of 25 mM
MgCl2 (Promega), 0.4 μl of deoxyribo-nucleotide triphos-
phate mix (10 mM each dNTP, Promega), 0.5 μl (5 IU/μl)
of Taq polymerase (Promega), 1 μl (0.25 μM) primers
(IDT), and 2.0 μl of template DNA. The PCR products and
molecular markers were electrophoresed in 2% agarose gel
with Tris-acetate-EDTA electrophoresis buffer. The size
markers were 100 bp ladder (Promega, USA). The PCR
amplification for each primer pair was repeated at least
thrice. Bands were visualized by the imaging system (Gel
Doc 2000, Gel Documentation System, Bio Rad, UK) after
being stained with ethidium bromide.
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Statistical method
Results are expressed as mean±standard deviation for
continuous variables (e.g., age) and number (percentage) for
categorical data (e.g., gender, stool culture, and diarrhea).
Univariate analysis was performed by using the independent
sample t test, Pearson Chi-square test, and Fisher exact test
where appropriate. A p value of <0.05 was considered as
statistically significant. All p values were two sided.
Statistical interpretation of data was performed by using the
computerized software program SPSS version 16.0.
Results
The age and sex of the patients were not related to the
positivity of D. fragilis and B. hominis when culture was
used as the diagnostic test for D. fragilis and B. hominis.
One hundred ninety-three (59%) had diarrhea, and 71
(52%) had abdominal pain.
Distribution and diagnostic yield of various tests
for B. hominis
B. hominis was positive by microscopy in 33% (110/330),
culture in 35% (115/330), and PCR in 33% (108/330;
Table 2). Microscopy for B. hominis was positive in 76%
(83/110) in patients fulfilling the criteria of IBS compared
to 24% (27/110) in control (p<0.001; Table 3). Culture for
B. hominis was positive in 78% (90/115) in IBS compared
to 22% (25/115) in control (p<0.001). PCR for B. hominis
was positive in 69% (75/108) in IBS compared to 31% (33/
108) in control (p<0.001; Table 3).
Distribution and diagnostic yield of various tests
for D. fragilis
D. fragilis was positive by microscopy in 2% (7/330),
culture in 3% (11/330), and PCR in 2% (6/330), respec-
tively (Fig 1; Table 2). Microscopy for D. fragilis was
positive in 86% (6/7) in IBS compared to 14% (1/7) in
control (p=0.123; Table 3). Culture for D. fragilis was
positive in 64% (7/11) in IBS compared to 36% (4/11) in
control (p=0.425; Table 3). PCR for D. fragilis was
positive in 86% (6/6) in IBS compared to none in control
(p=0.030; Table 3).
Coinfection with B. hominis and D. fragilis in different
groups
Microscopy was positive for both B. hominis and D. fragilis
in 3% (5/171) with IBS compared to zero (0/159) in control
(p=0.061; Table 2). Culture for both B. hominis and D.
fragilis was positive in 2.3% (4/171) with IBS compared to
zero (0/159) in control (p=0.123; Table 3). PCR was positive
for both B. hominis and D. fragilis in 3% (5/171) with IBS
compared to zero (0/159) in control (p=0.061; Table 3).
Comparison of culture for B. hominis and D. fragilis
with other test
In patients with IBS, B. hominis culture was positive in 90,
while microscopy for B. hominis was positive in 82% (74/
90; p<0.001) and PCR in 76% (68/90; p<0.001). In IBS
patients, D. fragilis was positive in seven (4%) with culture,




Positive 110 (33) 115 (35) 108 (33)
Negative 220 (67) 215 (65) 222 (67)
Dientamoeba fragilis
Positive 7 (2) 11 (3) 6 (2)
Negative 323 (98) 319 (97) 324 (98)
Blastocystis hominis and Dientamoeba fragilis
Positive 5 (2) 4 (1) 5 (2)
Negative 325 (98) 326 (99) 325 (98)
Table 1 Primer sequences used for Blastocystis hominis and Dientamoeba fragilis
Primer sequences 5′–3′ Amplified product size, bp PCR cycles
Blastocystis hominis 94°C for 3 min; 94°C for 30 min, 57°C
for 1 min 30 s, 72°C for 2 min (35 cycles);
72°C 7 min
SR1a F GCT TAT CTG GTT GATCCT
GCC AGT AGT
1,800
SR2 R TGA TCC TTC CGC AGG
TTC ACC TA
Dientamoeba fragilis 94°C for 5 min; 94°C for 1 min, 56°C
for 1 min 30 s, 72°C for 2 min (35 cycles);
72°C 5 min
TRD3b F GATCCAACGGCAGGTTCACCTACC 1,700
TRD5 R GATACTTGGTTGATCCTGCCAAGG
aYoshikawa et al. (2000)
b Silberman et al. (1996)
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while microscopy for D. fragilis was positive in 57% (4/7;
p<0.001), and PCR for D. fragilis was not positive in any
patients 0/7 (p=1).
Discussion
This study showed B. hominis was significantly positive in
IBS while D. fragilis was positive in only 4%. In patients
with IBS, B. hominis culture was significantly positive
compared to microscopy and PCR for B. hominis. Similarly,
culture of D. fragilis had a better yield compared to
microscopy with modified trichrome staining and PCR.
Coinfection with both B. hominis and D. fragilis in IBS
patients was documented in 3% with culture and 2.3% by
microscopy. B. hominis and D. fragilis infections did not
show any age and gender distribution. However, one third of
the D. fragilis infections were in patients who were in their
twenties. None of the patients with D. fragilis demonstrated
concomitant infection with E. vermicularis.
The implications of this study are that B. hominis are
found with a higher frequency in our IBS patients
compared to D. fragilis. The coinfection of B. hominis
and D. fragilis was seen in only IBS group and none in the
fecal samples from control group comprising of healthy
individuals without gastrointestinal symptoms. This study
has shown that D. fragilis was associated with IBS-like
symptoms in our patients, though it has a low prevalence. It
is still possible that we were not able to document all the D.
fragilis infections in spite of using three different modal-
ities, i.e., microscopy with modified trichrome staining of
fixed stool specimen, culture of stool specimens, and PCR
examination of unfixed stool specimens. It is possible that
if we examined three fixed and three unfixed stool speci-
mens from each of these patients, the yield might have
increased. Also, increasing number of symptomatic patients
would have helped. Windsor et al. found D. fragilis culture
has the best yield compared to microscopy with modified
iron-hematoxylin staining of stool specimen (Windsor et al.
2003). An Australian study previously described an
association between D. fragilis and IBS with 21 IBS
patients diagnosed with concurrent D. fragilis infection
(Brody et al. 2002). In another prospective study, 6,750
fecal samples were examined for D. fragilis. Trophozoites
of D. fragilis were detected in 60 (0.9%) patients by
permanent staining, using a modified iron-hematoxylin
stain that was confirmed by PCR (Stark et al. 2005).
Chronic symptoms were present in 32% with diarrhea
and abdominal pain present in all of these patients (Stark et
Fig. 1 Dientamoeba fragilis in stool specimen stained with modified
trichrome stain under ×100 magnification
Table 3 Comparison of Blastocystis hominis and Dientamoeba
fragilis in different groups
IBS, n=171 Control, n=159 P value
Blastocystis hominis
Microscopy
Positive 83 (48) 27 (17) <0.001
Negative 88 (52) 132 (83)
Culture
Positive 90 (53) 25 (16) <0.001
Negative 81 (47) 134 (84)
PCR
Positive 75 (44) 33 (21) <0.001
Negative 96 (56) 126 (79)
Dientamoeba fragilis
Microscopy
Positive 6 (4) 27 (17) 0.123
Negative 165(96) 132 (83)
Culture
Positive 7 (4) 4 (2) 0.545
Negative 164 (96) 155 (98)
PCR
Positive 6 (4) 0 (0) 0.030





Positive 5 (3) 0 (0) 0.061
Negative 166 (97) 159 (100)
Culture
Positive 4 (2) 0 (0) 0.124
Negative 167 (98) 159 (100)
PCR
Positive 5 (3) 0 (0) 0.061
Negative 166 (97) 159 (100)
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al. 2005). In the control group comprising of 900 stool
samples from patients without gastrointestinal symptoms,
no D. fragilis was detected by permanent staining (Stark et
al. 2005). Our results concur with that of Stark et al. (2005).
This is the first report of documentation of D. fragilis in our
population. It was found infrequently in our patients with
IBS. D. fragilis is a pathogenic organism rather than a
commensal, as diarrhea and abdominal pain were the most
common symptoms in both acute and chronic infections
(Johnson et al. 2004; Stark et al. 2005; Dobell 1940;
Windsor and Johnson 1999; Yang and Scholten 1977). We
also did not find any correlation between D. fragilis and E.
vermicularis, a proposed vector of transmission for D.
fragilis in keeping with previous study (Stark et al. 2005).
The results of this study concur with a previous study that
culture of B. hominis has a better yield than that of
microscopy (Zaman and Khan 1994). However, B. hominis
culture yield was not significantly different from B. hominis
PCR. In recent years, studies have suggested that there are
genotypes of B. hominis associated with symptomatic and
asymptomatic states (Hussein et al. 2008; Tan 2008; Yan et
al. 2006). Different degrees of pathological changes were
present among infected rats by symptomatic subtypes 1, 3,
and 4 compared with asymptomatic subtypes, e.g., 2, 3, and
4 (Hussein et al. 2008). The moderate and severe degree of
pathological changes was found only in symptomatic
subtypes infected rats, while mild degree was found only
in asymptomatic subtypes infected rats (Hussein et al. 2008).
The intestinal cell permeability was increased in symptom-
atic subtype 1 compared to symptomatic subtypes, e.g., 3
and 4, infected rats (Hussein et al. 2008). Minimal effects
were found in the asymptomatic and control groups. These
results proved that subtype 1 was clinically and statistically
highly relevant to the pathogenicity of B. hominis, while
subtype 2 was irrelevant (Hussein et al. 2008). Also, the
results suggested the presence of pathogenic and nonpatho-
genic strains among subtypes 3 and 4 (Hussein et al. 2008).
A study from China also described a possible relationship
between subtype 1 and a pathogenic potential of B. hominis
(Yan et al. 2006). Similarly, Blastocystis subtype 3 was
described as the most dominant genotype in asymptomatic
individual, and subtype 1 determined all of symptomatic
patients in studies from Turkey and Pakistan (Eroglu et al.
2009; Yakoob et al. 2010). D. fragilis prevalence appears to
be low in our IBS population.
In conclusion, we demonstrated presentation of B.
hominis and D. fragilis infections with symptoms of IBS;
however, only a prospective study with a larger sample size
is required to confirm this association of D. fragilis with
IBS-like symptoms in our population.
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